KR20150039130A - 유방 종양의 예방 및 치료를 위한 울리프리스탈 아세테이트 - Google Patents

유방 종양의 예방 및 치료를 위한 울리프리스탈 아세테이트 Download PDF

Info

Publication number
KR20150039130A
KR20150039130A KR1020147036629A KR20147036629A KR20150039130A KR 20150039130 A KR20150039130 A KR 20150039130A KR 1020147036629 A KR1020147036629 A KR 1020147036629A KR 20147036629 A KR20147036629 A KR 20147036629A KR 20150039130 A KR20150039130 A KR 20150039130A
Authority
KR
South Korea
Prior art keywords
upa
cells
treatment
breast
hbe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147036629A
Other languages
English (en)
Korean (ko)
Inventor
미셸르 헤쉬-히공
델핀느 르비
에린 게이너
안느 곰뻴
안느 곰?
빠트리씨아 포르게즈
로딘느 데즈허모-꼬뮤날
Original Assignee
라보라토이레 에이치알에이 파르마
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토이레 에이치알에이 파르마, 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) filed Critical 라보라토이레 에이치알에이 파르마
Publication of KR20150039130A publication Critical patent/KR20150039130A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147036629A 2012-05-25 2013-05-24 유방 종양의 예방 및 치료를 위한 울리프리스탈 아세테이트 Abandoned KR20150039130A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305586.5 2012-05-25
EP12305586 2012-05-25
PCT/EP2013/060801 WO2013175009A1 (en) 2012-05-25 2013-05-24 Ulipristal acetate for prevention and treatment of breast tumors

Publications (1)

Publication Number Publication Date
KR20150039130A true KR20150039130A (ko) 2015-04-09

Family

ID=48471021

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147036629A Abandoned KR20150039130A (ko) 2012-05-25 2013-05-24 유방 종양의 예방 및 치료를 위한 울리프리스탈 아세테이트

Country Status (10)

Country Link
US (2) US20150133418A1 (enExample)
EP (1) EP2854817B1 (enExample)
JP (1) JP6322623B2 (enExample)
KR (1) KR20150039130A (enExample)
AU (1) AU2013265163B2 (enExample)
CA (1) CA2874530A1 (enExample)
ES (1) ES2672727T3 (enExample)
HU (1) HUE037889T2 (enExample)
IL (1) IL235847B (enExample)
WO (1) WO2013175009A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240123870A (ko) 2023-02-07 2024-08-16 재단법인 아산사회복지재단 항암제에 대한 치료 반응성을 예측하기 위한 조성물 및 이의 용도

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5965377A (en) 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
US6514713B1 (en) 2001-07-03 2003-02-04 Hybritech Incorporated Methods of detecting BRCA1 mutations
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240123870A (ko) 2023-02-07 2024-08-16 재단법인 아산사회복지재단 항암제에 대한 치료 반응성을 예측하기 위한 조성물 및 이의 용도

Also Published As

Publication number Publication date
IL235847B (en) 2020-03-31
HUE037889T2 (hu) 2018-09-28
IL235847A0 (en) 2015-01-29
AU2013265163A1 (en) 2014-12-18
JP6322623B2 (ja) 2018-05-09
ES2672727T3 (es) 2018-06-15
WO2013175009A1 (en) 2013-11-28
EP2854817A1 (en) 2015-04-08
US9814732B2 (en) 2017-11-14
EP2854817B1 (en) 2018-03-21
US20170014426A1 (en) 2017-01-19
CA2874530A1 (en) 2013-11-28
JP2015520763A (ja) 2015-07-23
AU2013265163B2 (en) 2017-08-10
US20150133418A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
Russo et al. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells
Maruo et al. Sex steroidal regulation of uterine leiomyoma growth and apoptosis
Bulun et al. Aromatase in aging women
Portman et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women
Yuan et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells
Communal et al. Ulipristal acetate does not impact human normal breast tissue
To et al. Estradiol regulates Tumor Necrosis Factor-α expression and secretion in Estrogen Receptor positive breast cancer cells
Russo et al. Primary prevention of breast cancer by hormone-induced differentiation
Schafer et al. A mechanism of drug resistance to tamoxifen in breast cancer
Zhao et al. Estrogen-induced CCN1 is critical for establishment of endometriosis-like lesions in mice
US9814732B2 (en) Ulipristal acetate for prevention and treatment of breast tumors
Lim et al. Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780
Chinigarzadeh et al. Genistein-induced fluid accumulation in ovariectomised rats' uteri is associated with increased cystic fibrosis transmembrane regulator expression
Petit et al. Progestins induce catalase activities in breast cancer cells through PRB isoform: correlation with cell growth inhibition
Wilkins et al. Therapeutic opportunities in noncutaneous melanoma
Panigrahy et al. Role of insulin sensitising agents in altering PSA level in PCOS
Giordano et al. Complex Interplay Between Obesity and BRCA1/2‐Associated Breast Cancer: An Overview
Schoenlein et al. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer
Fang et al. Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells
Sadarangani et al. In vivo and in vitro estrogenic and progestagenic actions of Tibolone
CN108434137B (zh) 一种治疗前列腺癌的组合物
Isaksson et al. p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques
US9517240B2 (en) Methods and compositions for cancer prevention and treatment
WO2019166430A1 (en) Estriol component for use in the treatment of er-positive cancers
WO2008039482A2 (en) Methods and compositions for cancer prevention and treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190517

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191203

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200228

PC1904 Unpaid initial registration fee